¼¼°èÀÇ ±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ Ä¡·á ½ÃÀå : ¼ºÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Amyotrophic Lateral Sclerosis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1620455
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 131 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±ÙÀ§Ã༺ Ãø»ö °æÈ­Áõ(ALS) Ä¡·á ¼¼°è ½ÃÀåÀº 2023³â¿¡ 7¾ï 1,330¸¸ ´Þ·¯·Î Æò°¡µÇ¾î 2024-2032³â¿¡ °ÉÃÄ CAGR 5.5%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áø´Ü ±â¼úÀÇ »ó´çÇÑ Áøº¸·Î ALSÀÇ Á¶±â ¹ß°ß°ú °ü¸®°¡ °­È­µÇ¾ú½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç, ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ÀÇ Çâ»óÀ¸·Î, ÀÇ·á Á¦°ø¾÷ü´Â º¸´Ù ºü¸¥ ´Ü°è¿¡¼­ ALS¸¦ Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾î, ¸ÂÃã Ä¡·á °èȹÀÌ ¿ëÀÌÇÏ°Ô µÇ¾î, ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¾à¼öó¸®, Áٱ⠼¼Æ÷ Ä¡·á ¹× ±âŸ Á¢±Ù¹ýÀ¸·Î ³ª´¹´Ï´Ù.

2023³â¿¡´Â ¾à ¿ä¹ý ºÎ¹®ÀÌ 4¾ï 7,970¸¸ ´Þ·¯·Î ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù. ¸±Á¹ ¹× ¿¡´Ù¶óº»°ú °°Àº Ä¡·á´Â »ýÁ¸ ±â°£ÀÇ ¿¬Àå°ú ½Å°æ ¼¼Æ÷ Àå¾ÖÀÇ ¿ÏÈ­¸¦ ¸ñÀûÀ¸·Î ÀϹÝÀûÀ¸·Î »ç¿ëµÇ°í ÀÖÀ¸¸ç, ALS Ä¡·á¿¡ À־ÀÇ ÁÖ¿äÇÑ ¼ö¿ä ºÎ¹®¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. »ê¹ß¼º ALS´Â °¡Àå ÈçÇÑ º´ÇüÀ̸ç, Áõ·ÊÀÇ 90-95%¸¦ Â÷ÁöÇÕ´Ï´Ù.

»ê¹ß¼º ALS¿¡´Â ¸íÈ®ÇÑ À¯ÀüÀû °ü·Ã¼ºÀÌ ¾ø±â ¶§¹®¿¡ °¡Á·¼º ALS¿Í ºñ±³ÇÏ¿© Ä¡·á¿¡ Ãß°¡ÀûÀÎ °úÁ¦°¡ ÀÖ½À´Ï´Ù. º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ýÀ» ¸ð»öÇϱâ À§ÇØ ¼ö¸¹Àº ÀÓ»ó °Ë»ç°¡ ÁøÇà ÁßÀ̸ç, ALS ȯÀÚ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀÇ È®´ë¿¡ ´ëÇÑ ¹Ì±¹ÀÇ Çå½ÅÀ» ¹Ý¿µÇÕ´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ³â 2023³â
¿¹Ãø³â 2024-2032³â
½ÃÀÛ±Ý¾× 7¾ï 1,330¸¸ ´Þ·¯
¿¹Ãø ±Ý¾× 11¾ï ´Þ·¯
CAGR 5.5%

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áúȯ À¯Çüº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 713.3 million in 2023 and is expected to grow at a CAGR of 5.5% from 2024 to 2032. This growth is driven by the increasing prevalence of ALS, growing awareness about the condition, advancements in therapeutic technologies, and the continuous development of innovative treatment methods. Significant advancements in diagnostic technologies have enhanced the early detection and management of ALS. Improved neuroimaging techniques, genetic testing, and biomarker research allows healthcare providers to diagnose the disease at earlier stages, facilitating personalized treatment plans that contribute to market expansion. In terms of treatment types, the market is divided into medication, stem cell therapy, and other approaches.

In 2023, the medication segment led the market with a value of USD 479.7 million. This segment focuses on pharmaceutical treatments aimed at managing ALS symptoms and slowing disease progression. Medications like riluzole and edaravone are commonly used to prolong survival and reduce neuron damage, thereby addressing a key area of demand in ALS treatment. When segmented by disease type, sporadic ALS dominated the market with 87.3% share in 2023. Sporadic ALS is the most common form of the disease, accounting for 90-95% of cases.

It lacks a clear genetic link, which poses additional challenges in treatment compared to familial ALS. However, the widespread prevalence of this form continues to drive demand for innovative therapeutic solutions. North America plays a crucial role in the ALS treatment market, with the region expected to grow at a CAGR of 5.2% and reach USD 515.6 million by 2032. The U.S. is a key contributor due to the high prevalence of ALS, supported by a strong healthcare infrastructure and significant research and development efforts. Numerous clinical trials are underway in the U.S. to explore more effective treatments, reflecting the country's commitment to expanding therapeutic options for ALS patients

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$713.3 Million
Forecast Value$1.1 Billion
CAGR5.5%

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â